-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Granahan Investment Management LLC Buys 691,029 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)
Granahan Investment Management LLC Buys 691,029 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)
Granahan Investment Management LLC boosted its stake in shares of ImmunoGen, Inc. (NASDAQ:IMGN – Get Rating) by 54.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,957,719 shares of the biotechnology company's stock after purchasing an additional 691,029 shares during the quarter. Granahan Investment Management LLC owned about 0.89% of ImmunoGen worth $9,319,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Xponance Inc. bought a new stake in shares of ImmunoGen in the first quarter valued at approximately $49,000. HighTower Advisors LLC acquired a new position in shares of ImmunoGen in the fourth quarter valued at $77,000. O Shaughnessy Asset Management LLC raised its stake in shares of ImmunoGen by 68.2% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 12,620 shares of the biotechnology company's stock valued at $94,000 after purchasing an additional 5,115 shares in the last quarter. XTX Topco Ltd acquired a new position in ImmunoGen during the first quarter worth $62,000. Finally, TFC Financial Management raised its stake in ImmunoGen by 18.1% during the first quarter. TFC Financial Management now owns 17,950 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 2,750 shares in the last quarter. Institutional investors own 95.58% of the company's stock.
Get ImmunoGen alerts:Analyst Upgrades and Downgrades
IMGN has been the subject of several recent analyst reports. Barclays initiated coverage on ImmunoGen in a research note on Friday. They set an "overweight" rating and a $8.00 price objective for the company. StockNews.com lowered ImmunoGen from a "hold" rating to a "sell" rating in a research note on Monday, August 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $9.80.
ImmunoGen Price Performance
ImmunoGen stock opened at $5.46 on Friday. The business's 50-day simple moving average is $5.39 and its 200 day simple moving average is $4.84. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -7.91 and a beta of 0.90. ImmunoGen, Inc. has a 12-month low of $3.10 and a 12-month high of $7.77.ImmunoGen (NASDAQ:IMGN – Get Rating) last posted its quarterly earnings results on Friday, July 29th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.03). The firm had revenue of $14.20 million during the quarter, compared to the consensus estimate of $16.18 million. ImmunoGen had a negative net margin of 179.64% and a negative return on equity of 67.02%. ImmunoGen's revenue was down 16.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.15) EPS. As a group, sell-side analysts expect that ImmunoGen, Inc. will post -0.89 EPS for the current year.
About ImmunoGen
(Get Rating)
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
See Also
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
Granahan Investment Management LLC boosted its stake in shares of ImmunoGen, Inc. (NASDAQ:IMGN – Get Rating) by 54.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,957,719 shares of the biotechnology company's stock after purchasing an additional 691,029 shares during the quarter. Granahan Investment Management LLC owned about 0.89% of ImmunoGen worth $9,319,000 at the end of the most recent quarter.
根據Granahan Investment Management LLC最近向美國證券交易委員會(Securities&Exchange Commission)披露的信息,該公司在第一季度增持了免疫系統公司的股份(納斯達克代碼:IMGN-GET評級)54.6%。該公司在本季度額外購買了691,029股後,擁有1,957,719股這家生物技術公司的股票。截至最近一個季度末,Granahan Investment Management LLC擁有ImmunoGen約0.89%的股份,價值931.9萬美元。
Other large investors have also recently added to or reduced their stakes in the company. Xponance Inc. bought a new stake in shares of ImmunoGen in the first quarter valued at approximately $49,000. HighTower Advisors LLC acquired a new position in shares of ImmunoGen in the fourth quarter valued at $77,000. O Shaughnessy Asset Management LLC raised its stake in shares of ImmunoGen by 68.2% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 12,620 shares of the biotechnology company's stock valued at $94,000 after purchasing an additional 5,115 shares in the last quarter. XTX Topco Ltd acquired a new position in ImmunoGen during the first quarter worth $62,000. Finally, TFC Financial Management raised its stake in ImmunoGen by 18.1% during the first quarter. TFC Financial Management now owns 17,950 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 2,750 shares in the last quarter. Institutional investors own 95.58% of the company's stock.
其他大型投資者最近也增持或減持了該公司的股份。今年第一季度,Xponance Inc.購入了一批新股,價值約49,000美元。HighTower Advisors LLC在第四季度收購了ImmunoGen股票的新頭寸,價值77,000美元。O Shaughnessy Asset Management LLC在第四季度將其在ImmunoGen的股份增加了68.2%。O Shaughnessy Asset Management LLC現在擁有這家生物技術公司12,620股票,價值94,000美元,上個季度又購買了5,115股票。XTX Topco Ltd在第一季度收購了免疫遺傳公司的一個新頭寸,價值6.2萬美元。最後,TFC金融管理公司在第一季度將其在ImmunoGen的持股比例提高了18.1%。在上個季度增持了2,750股後,TFC金融管理公司現在持有這家生物技術公司17,950股股票,價值8.5萬美元。機構投資者持有該公司95.58%的股票。
Analyst Upgrades and Downgrades
分析師升級和下調評級
IMGN has been the subject of several recent analyst reports. Barclays initiated coverage on ImmunoGen in a research note on Friday. They set an "overweight" rating and a $8.00 price objective for the company. StockNews.com lowered ImmunoGen from a "hold" rating to a "sell" rating in a research note on Monday, August 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $9.80.
IMGN一直是最近幾份分析師報告的主題。巴克萊在週五的一份研究報告中啟動了對免疫基因的報道。他們為該公司設定了“增持”評級和8.00美元的目標價。在8月1日星期一的一份研究報告中,StockNews.com將免疫系統的評級從“持有”下調至“賣出”。一名投資分析師對該股的評級為賣出,兩名分析師的評級為持有,三名分析師的評級為買入。根據MarketBeat.com的數據,該公司目前的平均評級為持有,共識目標價為9.80美元。
ImmunoGen Price Performance
免疫發電性價比
ImmunoGen (NASDAQ:IMGN – Get Rating) last posted its quarterly earnings results on Friday, July 29th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.03). The firm had revenue of $14.20 million during the quarter, compared to the consensus estimate of $16.18 million. ImmunoGen had a negative net margin of 179.64% and a negative return on equity of 67.02%. ImmunoGen's revenue was down 16.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.15) EPS. As a group, sell-side analysts expect that ImmunoGen, Inc. will post -0.89 EPS for the current year.
免疫基因公司(納斯達克代碼:IMGN-GET Rating)上一次公佈季度收益是在7月29日星期五。這家生物技術公司公佈了該季度每股收益(EPS)(0.24美元),低於普遍預期的(0.21美元)和(0.03美元)。該公司本季度營收為1,420萬美元,而普遍預期為1,618萬美元。免疫基因公司的淨利潤率為負179.64%,淨資產回報率為負67.02%。免疫系統的營收同比下降了16.0%。在上一年的同一季度,該業務的每股收益為0.15美元。賣方分析師預計,作為一個整體,ImmunoGen,Inc.本年度每股收益將達到0.89美元。
About ImmunoGen
關於免疫基因
(Get Rating)
(獲取評級)
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
免疫基因公司是一家臨牀階段的生物技術公司,開發抗體-藥物結合(ADC)療法來治療癌症。該公司的候選產品包括針對葉酸受體α(FRA)的ADC Mirvetuximab soravtansine,它正處於治療對鉑耐藥的卵巢癌的第三階段臨牀試驗;以及Pivekimab Sunirine,一種針對CD123的ADC,正處於治療急性髓系白血病和原始漿細胞樣樹突狀細胞腫瘤的第二階段臨牀試驗。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免費獲取StockNews.com關於免疫基因的研究報告(IMGN)
- MarketBeat:回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦,這些股票可能表現優異
- DocuSign是否即將發生重大逆轉?
- 石油和天然氣股票:投資可再生能源的安全途徑
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受《免疫基因日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對免疫系統及相關公司評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧